Dicetech
Dicetech provides software that accelerates prostate MRI workflows and generates virtual biopsy maps from routine T2 images, eliminating the need for contrast injection. The platform runs on existing scanners, requiring only about twenty seconds of additional compute to produce a clinically actionable biomarker. It is clinically integrated with Siemens Healthineers equipment and deployed across seven hospitals in Italy and the UK.
- Healthcare Technology
- Digital Health
- Software Only
Funding
Raised to date
$120KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Prostate cancer diagnosis often relies on contrast-enhanced MRI and invasive biopsies, which carry risks of complications such as bleeding, infection, and sepsis. The conventional diagnostic pathway can involve long waitlists and delays, hampering timely detection and staging of clinically significant prostate cancer (csPCa).
Solution
MRmicro provides software that accelerates MRI acquisition and generates virtual biopsy maps from routine T2 images, removing the need for contrast injection and reducing unnecessary prostate biopsies. The software runs on existing scanners without hardware changes, requiring only about twenty seconds of additional compute to produce a clinically actionable biomarker. Advanced microstructure maps enable early detection and improved staging of csPCa, helping radiologists decide whether to biopsy and where. This contrast-free workflow shortens the diagnostic pathway, reducing waitlists from up to a year to just a few weeks and creating a less invasive, less stressful patient experience.
Target Audience
Primary customers are radiology departments and urology centers in hospitals that perform prostate MRI and need faster, less invasive cancer detection workflows.
Features
- Advanced microstructure analysis that produces virtual biopsy maps directly from routine T2-weighted images without contrast injection
- Ultra-fast compute of approximately 10-20 seconds per case on existing MRI scanners, accelerating the conventional multi-day pipeline
- Clinically validated biomarker for guiding biopsy decisions, with prospective trial evidence showing risk-stratification improvement and reduced unnecessary biopsies
- Cloud-free, on-scanner deployment integrated with Siemens Healthineers equipment, operational at seven hospitals across Italy and the UK
- CE marking in progress under Class IIa MDR, based on 12 years of academic research across leading institutions